SCHEDULE: RA Capital Increases Stake in Artiva Biotherapeutics

RA Capital Management has increased its beneficial ownership in Artiva Biotherapeutics to 36.6% following a series of open market purchases.

Summary

• RA Capital Management, L.P. and its affiliates increased their stake in Artiva Biotherapeutics, Inc. through a series of open market purchases between June 9 and June 15, 2026.
• The reporting persons now beneficially own 17,811,623 shares of common stock, representing 36.6% of the outstanding class.
• Purchases were made at prices ranging from $6.77 to $9.00 per share.
• The reporting group includes RA Capital Management, Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive signal, as a major institutional investor is actively increasing its position in the open market, suggesting strong internal belief in the company's valuation and future.

Positives

• Significant increase in share accumulation by a major institutional investor, signaling confidence in the company's long-term prospects.
• The reporting persons have demonstrated consistent support through continued investment.

Negatives

• Concentration of ownership may limit the free float of shares available to other investors.
• The presence of a 'Beneficial Ownership Blocker' on pre-funded warrants limits the immediate conversion of these instruments into common stock.

Risks

• Market volatility affecting the price of common stock.
• Regulatory and clinical risks inherent to the biotechnology sector.
• Potential for future dilution if additional offerings occur.

Future Outlook

The filing does not provide specific forward-looking guidance regarding the company's operations, but indicates continued investment interest from a major shareholder.

Management Comments

• The reporting persons disclaim beneficial ownership of the securities reported other than for the purpose of determining their obligations under Section 13(d) of the Act.

Industry Context

StockSavvy.ai notes that aggressive accumulation by specialized healthcare funds like RA Capital is a common indicator of institutional conviction in clinical-stage biotech pipelines, often preceding or following significant data readouts or strategic milestones.

Comparison to Industry Standards

• The 36.6% ownership stake is significant and reflects a high-conviction position typical of venture-backed biotech firms post-IPO.
• The use of pre-funded warrants with ownership blockers is a standard mechanism in biotech financing to manage regulatory compliance regarding beneficial ownership thresholds.

Legal Proceedings

• None reported.

Related Party Transactions

• The reporting persons are investment advisers and general partners to the funds holding the shares.

Stakeholder Impact

• Shareholders may view the increased institutional stake as a vote of confidence.
• Reduced liquidity may occur due to the concentration of shares held by a single reporting group.

Next Steps

• Continued monitoring of further 13D filings by RA Capital.
• Observation of potential impact on share price due to increased institutional demand.

Key Dates

Recommendation

The active accumulation of shares by a sophisticated healthcare-focused investment firm like RA Capital often serves as a bullish signal for retail and institutional investors, suggesting that the current market price may undervalue the company's long-term potential.

Keywords

Artiva Biotherapeutics, RA Capital Management, Schedule 13D, Biotechnology, Institutional Ownership, Common Stock